In comparison, NGS provides vastly greater genetic information than simple point mutations, and costs approximately €415 (approximately 610 CAD).27 Both NGS and MALD-TOF MS platforms have sensitivity and specificity approaching 98% to 100% in detecting BRAF mutations in melanoma.24 RT-PCR based techniques also have comparable sensitivity and specificity to NGS and MALDI-TOF MS.24 Furthermore, each test is able to detect nearly all clinically relevant genetic targets. The gene discussed is BRAF; the disease is melanoma.